Acta Ophthalmol

1. LINDBOE JB, Brynskov T, Sorensen TL, Schmidt Laugesen C, et al
   Real-world experiences with intravitreal treatment with ranibizumab and aflibercept for diabetic macular oedema 2008-2021.
   Acta Ophthalmol. 2024 Mar 25. doi: 10.1111/aos.16677.
   

   >> Share

   
   
2. HELOTERA H, Arffman M, Sund R, Keskimaki I, et al
   The incidence and prevalence of diabetic macular edema and proliferative diabetic retinopathy, their progression to visual impairment and patterns in their intravitreal treatment in the Finnish population.
   Acta Ophthalmol. 2024 Mar 24. doi: 10.1111/aos.16675.
   

   >> Share

   
   

   
   Am J Cardiol

3. AGARWAL S, Qamar U, Fujiwara Y, Guha A, et al
   The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes in Patients with Cancer: A Systematic Review and Meta-Analysis.
   Am J Cardiol. 2024 Feb 17:S0002-9149(24)00101.
   

   >> Share

   
   
4. PERERA S, Zheng Z, Wadhera R
   Cardiovascular Health, Lifestyle Factors, and Social Determinants Among Asian Sub-Populations in the US.
   Am J Cardiol. 2024 Feb 16:S0002-9149(24)00098.
   

   >> Share

   
   

   
   Ann Intern Med

5. GARABEDIAN LF, Zhang F, Costa R, Argetsinger S, et al
   Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.
   Ann Intern Med. 2024 Mar 26. doi: 10.7326/M23-1965.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

6. LUO X, Luan C, Zhou J, Ye Y, et al
   Glycolytic enzyme Enolase-1 regulates insulin gene expression in pancreatic beta-cell.
   Biochem Biophys Res Commun. 2024;706:149735.
   

   >> Share

   
   

   
   BMJ

7. CHRISTIE B
   Charity calls for Scottish government to increase access to diabetes technology.
   BMJ. 2024;384:q755.
   

   >> Share

   
   
8. MAHASE E
   Type 1 diabetes: Randox removes adverts after claims that it was using fear to sell genetic test.
   BMJ. 2024;384:q744.
   

   >> Share

   
   

   
   Diabetes

9. ABRAHAM A, Cule M, Thanaj M, Basty N, et al
   Genetic evidence for distinct biological mechanisms that link adiposity to type 2 diabetes: towards precision medicine.
   Diabetes. 2024 Mar 26:db231005. doi: 10.2337/db23-1005.
   

   >> Share

   
   
10. WILLIAMS RC, Hanson RL, Peters B, Kearns K, et al
    Epistasis Between HLA-DRB1*16:02:01 and SLC16A11 T-C-G-T-T Reduces Odds for Type 2 Diabetes in Southwest American Indians.
    Diabetes. 2024 Mar 26:db230925. doi: 10.2337/db23-0925.
    

    >> Share

    
    
11. FAWAZ S, Martin Alonso A, Qiu Y, Ramnath R, et al
    Adiponectin reduces glomerular endothelial glycocalyx disruption and restores glomerular barrier function in a mouse model of type 2 diabetes.
    Diabetes. 2024 Mar 26:db230455. doi: 10.2337/db23-0455.
    

    >> Share

    
    

    
    Diabetes Care

12. GARVEY WT, Cohen RM, Butera NM, Kazemi EJ, et al
    Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.
    Diabetes Care. 2024;47:562-570.
    

    >> Share

    
    
13. FOSS-FREITAS MC, Imam S, Neidert A, Gomes AD, et al
    Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy.
    Diabetes Care. 2024;47:653-659.
    

    >> Share

    
    
14. AL RIFAI M, Al-Mallah MH, Blaha MJ, Patel J, et al
    Epidemiology and Prognostic Implications of Coronary Artery Calcium in Asymptomatic Individuals With Prediabetes: A Multicohort Study.
    Diabetes Care. 2024;47:698-706.
    

    >> Share

    
    
15. ANTHONY MS, Aroda VR, Parlett LE, Djebarri L, et al
    Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
    Diabetes Care. 2024;47:712-719.
    

    >> Share

    
    
16. WEISSMAN YL, Calvarysky B, Shochat T, Korotkov Z, et al
    Disparities in Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Prescription and Dispensing in the Israeli Population-A Retrospective Cohort Study.
    Diabetes Care. 2024;47:692-697.
    

    >> Share

    
    
17. YUAN CY, Kong YW, Amoore T, Brown K, et al
    Improved Satisfaction While Maintaining Safety and High Time in Range (TIR) With a Medtronic Investigational Enhanced Advanced Hybrid Closed-Loop (e-AHCL) System.
    Diabetes Care. 2024;47:747-755.
    

    >> Share

    
    
18. CALIFF RM
    Erratum. Our National Approach to Diabetes. Diabetes Care 2023;46:252-254.
    Diabetes Care. 2024 Mar 22:dc24er05b. doi: 10.2337.
    

    >> Share

    
    
19. LORBER DL, ElSayed NA, Bannuru RR, Shah V, et al
    Diabetes Management in Detention Facilities: A Statement of the American Diabetes Association.
    Diabetes Care. 2024;47:544-555.
    

    >> Share

    
    
20. NINON F, Alice L, Marie-Amelie BM, Laurence B, et al
    Comment on Umapathysivam et al. Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium-Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction. Diabetes Care 2024;47:140-143.
    Diabetes Care. 2024;47:e35.
    

    >> Share

    
    
21. MALTESE G, Sinclair AJ
    Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004-2014.
    Diabetes Care. 2024;47:e32-e33.
    

    >> Share

    
    
22. ST-ONGE MP, Zuraikat FM, Laferrere B, Jelic S, et al
    Response to Comment on Zuraikat et al. Chronic Insufficient Sleep in Women Impairs Insulin Sensitivity Independent of Adiposity Changes: Results of a Randomized Trial. Diabetes Care 2024;47:117-125.
    Diabetes Care. 2024;47:e37-e38.
    

    >> Share

    
    
23. PAGE B
    About the Editor: Camille E. Powe, MD: Advancing Research for Diabetes and Pregnancy.
    Diabetes Care. 2024;47:518-519.
    

    >> Share

    
    
24. KAWADA T
    Comment on Zuraikat et al. Chronic Insufficient Sleep in Women Impairs Insulin Sensitivity Independent of Adiposity Changes: Results of a Randomized Trial. Diabetes Care 2024;47:117-125.
    Diabetes Care. 2024;47:e36.
    

    >> Share

    
    
25. NAKASONE Y, Yamashita K, Aizawa T
    Comment on Umapathysivam et al. Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium-Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction. Diabetes Care 2024;47:140-143.
    Diabetes Care. 2024;47:e34.
    

    >> Share

    
    
26. RIDDLE MC
    Individualizing Treatment of Type 2 Diabetes After Metformin: More Insights From GRADE.
    Diabetes Care. 2024;47:556-561.
    

    >> Share

    
    
27. JACOBSEN LM
    Prompt Recognition of New-Onset Type 1 Diabetes Is Everyone's Responsibility-Even on Weekends.
    Diabetes Care. 2024;47:646-648.
    

    >> Share

    
    
28. GIORGINO F, Franco DR, Nicolay C, Hemmingway A, et al
    Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.
    Diabetes Care. 2024 Mar 26:dc232366. doi: 10.2337/dc23-2366.
    

    >> Share

    
    
29. NAGEL KE, Ramachandran R, Lipska KJ
    Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications.
    Diabetes Care. 2024 Mar 27:dci230042. doi: 10.2337/dci23-0042.
    

    >> Share

    
    
30. ORLANDO G, Brown S, Jude E, Bowling FL, et al
    Acute Effects of Vibrating Insoles on Dynamic Balance and Gait Quality in Individuals With Diabetic Peripheral Neuropathy: A Randomized Crossover Study.
    Diabetes Care. 2024 Mar 27:dc231858. doi: 10.2337/dc23-1858.
    

    >> Share

    
    

    
    Diabetes Obes Metab

31. TOMLINSON JW
    Bardet-Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction.
    Diabetes Obes Metab. 2024;26 Suppl 2:13-24.
    

    >> Share

    
    
32. ZHANG Y, Yang D, Jia Q, Yan J, et al
    The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15557.
    

    >> Share

    
    
33. CARIOU B, Linge J, Neeland IJ, Dahlqvist Leinhard O, et al
    Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15566.
    

    >> Share

    
    
34. SUZUKI Y, Kaneko H, Nagasawa H, Okada A, et al
    Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.
    Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15561.
    

    >> Share

    
    
35. 
    Correction to 'In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank'.
    Diabetes Obes Metab. 2024 Mar 27. doi: 10.1111/dom.15591.
    

    >> Share

    
    

    
    Diabetologia

36. MARCOVECCHIO ML, Hendriks AEJ, Delfin C, Battelino T, et al
    The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults.
    Diabetologia. 2024 Mar 22. doi: 10.1007/s00125-024-06124.
    

    >> Share

    
    
37. VAN DEN BURG EL, Schoonakker MP, van Peet PG, van den Akker-van Marle EM, et al
    Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial.
    Diabetologia. 2024 Mar 28. doi: 10.1007/s00125-024-06137.
    

    >> Share

    
    
38. KORNUM DS, Bertoli D, Kufaishi H, Wegeberg AM, et al
    Transcutaneous vagal nerve stimulation for treating gastrointestinal symptoms in individuals with diabetes: a randomised, double-blind, sham-controlled, multicentre trial.
    Diabetologia. 2024 Mar 28. doi: 10.1007/s00125-024-06129.
    

    >> Share

    
    

    
    Eur J Endocrinol

39. AHN HY, Lee J, Kang J, Lee EK, et al
    Increased risk of diabetes mellitus and hyperlipidemia in patients with differentiated thyroid cancer.
    Eur J Endocrinol. 2024;190:248-255.
    

    >> Share

    
    

    
    Invest Ophthalmol Vis Sci

40. MCCURRY CM, Sunilkumar S, Subrahmanian SM, Yerlikaya EI, et al
    NLRP3 Inflammasome Priming in the Retina of Diabetic Mice Requires REDD1-Dependent Activation of GSK3beta.
    Invest Ophthalmol Vis Sci. 2024;65:34.
    

    >> Share

    
    
41. GAO N, Yu FS
    Lack of Elevated Expression of TGFbeta3 Contributes to the Delay of Epithelial Wound Healing in Diabetic Corneas.
    Invest Ophthalmol Vis Sci. 2024;65:35.
    

    >> Share

    
    

    
    J Clin Endocrinol Metab

42. QIU Z, Lee DH, Lu Q, Li R, et al
    Associations of Regional Body Fat with Risk of Cardiovascular Disease and Mortality among Individuals with Type 2 Diabetes.
    J Clin Endocrinol Metab. 2024 Mar 26:dgae192. doi: 10.1210.
    

    >> Share

    
    
43. LIU JJ, Liu S, Zheng H, Lee J, et al
    Urine tricarboxylic acid cycle metabolites and risk of end stage kidney disease in patients with type 2 diabetes.
    J Clin Endocrinol Metab. 2024 Mar 28:dgae199. doi: 10.1210.
    

    >> Share

    
    

    
    JAMA

44. MOZAFFARIAN D
    GLP-1 Agonists for Obesity-A New Recipe for Success?
    JAMA. 2024;331:1007-1008.
    

    >> Share

    
    

    
    PLoS One

45. ZHANG F, Chen X, Yang M, Shen X, et al
    Metabolic impairments associated with type 2 diabetes mellitus and the potential effects of exercise therapy: An exploratory randomized trial based on untargeted metabolomics.
    PLoS One. 2024;19:e0300593.
    

    >> Share

    
    
46. YANG J, Wang G, Xiao X, Bao M, et al
    Explainable ensemble learning method for OCT detection with transfer learning.
    PLoS One. 2024;19:e0296175.
    

    >> Share

    
    
47. BRNABIC AJM, Curtis SE, Johnston JA, Lo A, et al
    Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework.
    PLoS One. 2024;19:e0300708.
    

    >> Share

    
    
48. BORAI A, Ichihara K, Bahijri S, Alsofyani A, et al
    Establishment of reference interval for hemoglobin A1C and other hemoglobin subfractions for healthy Saudi adults.
    PLoS One. 2024;19:e0300028.
    

    >> Share

    
    
49. ABEBE MG, Alemayehu AM, Munaw MB, Tilahun MM, et al
    Prevalence and associated factors of refractive error among adults in South Ethiopia, a community-based cross-sectional study.
    PLoS One. 2024;19:e0298960.
    

    >> Share

    
    
50. MIHEVC M, Mirosevic S, Lukancic MM, Potocnik TV, et al
    Assessing the reliability and validity of the Slovenian version of the Appraisal of Diabetes Scale (ADS-S) in type 2 diabetes patients.
    PLoS One. 2024;19:e0300797.
    

    >> Share

    
    
51. GUO H, Zhang L, He H, Wang L, et al
    Risk factors for catheter-associated bloodstream infection in hemodialysis patients: A meta-analysis.
    PLoS One. 2024;19:e0299715.
    

    >> Share

    
    
52. DIMNJAKOVIC J, Buble T, Ivanko P, Poljicanin T, et al
    Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis.
    PLoS One. 2024;19:e0301056.
    

    >> Share

    
    
53. WANG S, Li J, Zhao Y
    Construction and analysis of a network of exercise-induced mitochondria-related non-coding RNA in the regulation of diabetic cardiomyopathy.
    PLoS One. 2024;19:e0297848.
    

    >> Share

    
    
54. BAUVIN P, Delacote C, Wandji LCN, Lassailly G, et al
    Early prediction of the impact of public health policies on obesity and lifetime risk of type 2 diabetes: A modelling approach.
    PLoS One. 2024;19:e0301463.
    

    >> Share

    
    

    
    Retina

55. SU T, Lai D, Wu Y, Gu C, et al
    COMPARISON OF THE EFFICACY AND SAFETY OF RANIBIZUMAB 0.5 MG VERSUS 1.0 MG WITH PARS PLANA VITRECTOMY FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY: A Randomized Controlled Trial.
    Retina. 2024;44:680-688.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share